التفاصيل البيبلوغرافية
| العنوان: |
2024 update in heart failure |
| المؤلفون: |
Alberto Beghini, Antonio Maria Sammartino, Zoltán Papp, Stephan vonHaehling, Jan Biegus, Piotr Ponikowski, Marianna Adamo, Luigi Falco, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra, Daniela Tomasoni |
| المصدر: |
ESC Heart Failure, Vol 12, Iss 1, Pp 8-42 (2025) |
| بيانات النشر: |
Wiley, 2025. |
| سنة النشر: |
2025 |
| المجموعة: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| مصطلحات موضوعية: |
comorbidities, finerenone, heart failure, prevention, prognosis, SGLT2 inhibitors, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| الوصف: |
Abstract In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the results of the last years of science. First, two drugs, sodium–glucose co‐transporter‐2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for the prevention of HF in patients with diabetic chronic kidney disease (CKD). Second, SGLT2 inhibitors are now recommended for the treatment of HF across the entire left ventricular ejection fraction spectrum. The benefits of quadruple therapy in patients with HF with reduced ejection fraction (HFrEF) are well established. Its rapid and early up‐titration along with a close follow‐up with frequent clinical and laboratory re‐assessment after an episode of acute HF (the so‐called ‘high‐intensity care’ strategy) was associated with better outcomes in the STRONG‐HF trial. Patients experiencing an episode of worsening HF might require a fifth drug, vericiguat. In the STEP‐HFpEF‐DM and STEP‐HFpEF trials, semaglutide 2.4 mg once weekly administered for 1 year decreased body weight and significantly improved quality of life and the 6 min walk distance in obese patients with HF with preserved ejection fraction (HFpEF) with or without a history of diabetes. Further data on safety and efficacy, including also hard endpoints, are needed to support the addition of acetazolamide or hydrochlorothiazide to a standard diuretic regimen in patients hospitalized due to acute HF. In the meantime, PUSH‐AHF supported the use of natriuresis‐guided diuretic therapy. Further options and most recent evidence for the treatment of HF, including specific drugs for cardiomyopathies (i.e., mavacamten in hypertrophic cardiomyopathy and tafamidis in transthyretin cardiac amyloidosis), device therapies, cardiac contractility modulation and percutaneous treatment of valvulopathies, with the recent finding from the TRILUMINATE Pivotal trial, are also reviewed in this article. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2055-5822 |
| Relation: |
https://doaj.org/toc/2055-5822 |
| DOI: |
10.1002/ehf2.14857 |
| URL الوصول: |
https://doaj.org/article/4fb146934c2544e89339c9379c54ce1d |
| رقم الانضمام: |
edsdoj.4fb146934c2544e89339c9379c54ce1d |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder